Key Takeaway: The article discusses Atebimetinib's role in inhibiting MEK and its effects on RAS-mutant tumors. It highlights the drug's potential to constrain adaptive and acquired alterations in the MAPK axis. However, specific details about clinical outcomes or study results are not provided.
Price reaction · baseline $5.56 (2026-04-17 close) · hit pre-market · 1 other IMRX headline(s) in the window, move may be shared
day 0 close
-0.5%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
11.4%
average across 8 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 Monotherapy
Phase 1 · Advanced Solid Tumor
Full Press Release Details
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.